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Abstract: Tuberculosis (TB) is still a major public health issue in developing countries, and its 
chemotherapy is compromised by poor drug compliance and severe side effects. This study aimed 
to synthesize and characterize new multimodal PEGylated liposomes encapsulated with clinically 
commonly used anti-TB drugs with linkage to small interfering RNA (siRNA) against transforming 
growth factor-β1 (TGF-β1). The novel NP-siRNA liposomes could target THP-1-derived human 
macrophages that were the host cells of mycobacterium infection. The biological effects of the 
NP-siRNA liposomes were evaluated on cell cycle distribution, apoptosis, autophagy, and the gene 
silencing efficiency of TGF-β1 siRNA in human macrophages. We also explored the proteomic 
responses to the newly synthesized NP-siRNA liposomes using the stable isotope labeling with 
amino acids in cell culture approach. The results showed that the multifunctional PEGylated lipo-
somes were successfully synthesized and chemically characterized with a mean size of 265.1 nm. 
The novel NP-siRNA liposomes functionalized with the anti-TB drugs and TGF-β1 siRNA were 
endocytosed efficiently by human macrophages as visualized by transmission electron microscopy 
and scanning electron microscopy. Furthermore, the liposomes showed a low cytotoxicity toward 
human macrophages. There was no significant effect on cell cycle distribution and apoptosis in 
THP-1-derived macrophages after drug exposure at concentrations ranging from 2.5 to 62.5 μg/mL. 
Notably, there was a 6.4-fold increase in the autophagy of human macrophages when treated with 
the NP-siRNA liposomes at 62.5 μg/mL. In addition, the TGF-β1 and nuclear factor-κB expres-
sion levels were downregulated by the NP-siRNA liposomes in THP-1-derived macrophages. The 
Ingenuity Pathway Analysis data showed that there were over 40 signaling pathways involved 
in the proteomic responses to NP-siRNA liposome exposure in human macrophages, with 160 
proteins mapped. The top five canonical signaling pathways were eukaryotic initiation factor 2 
signaling, actin cytoskeleton signaling, remodeling of epithelial adherens junctions, epithelial 
adherens junction signaling, and Rho GDP-dissociation inhibitor signaling pathways. Collectively, 
the novel synthetic targeting liposomes represent a promising delivery system for anti-TB drugs 
to human macrophages with good selectivity and minimal cytotoxicity.
Keywords: tuberculosis, cytokine, liposome, apoptosis, autophagy, cell cycle, proteomics, 
SILAC, NF-κB, interleukin
Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains a major global 
health problem and ranks as the second leading cause of death from an infectious 
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disease worldwide after human immunodeficiency virus 
(HIV), despite the discovery of effective and affordable 
chemotherapy more than 50 years ago.1–6 According to the 
data of World Health Organization (WHO),5 an estimated 
9 million people developed TB, and 1.5 million (including 
HIV-positive patients who died of TB) died from the disease 
worldwide, in 2013. The deaths included 1.1 million among 
HIV-negative and 360,000 among HIV-positive, people. 
Approximately 78% of the overall total TB deaths, and 
73% of TB deaths among HIV-negative people occurred in 
the African and Southeast Asian Regions in 2013.5 Of the 
estimated 9 million new TB cases worldwide in 2013, about 
57% of TB cases occurred in men; there were an estimated 
3.3 million cases and 510,000 TB deaths among women, as 
well as an estimated 550,000 cases and 80,000 deaths 
among children.5 The African and Southeast Asian Regions 
accounted for 69% of the cases among women. Additionally, 
half of the HIV-positive people who died from TB in 2013 
were women.5 Most of the estimated number of cases 
in 2013 occurred in Asia (56%) and the African Region 
(29%); smaller proportions of cases occurred in the Eastern 
Mediterranean Region (8%), the European Region (4%), and 
the Region of the Americas (3%).5 India and the People’s 
Republic of China alone accounted for 24% and 11% of the 
total cases in 2013, respectively. In the US, there were 9,582 
new TB cases in 2013, with an incidence of 3.0 cases/100,000 
population.7 About 65% of these TB cases were in people 
born outside the US, and more than half came from five coun-
tries including Mexico, the Philippines, India, Vietnam, and 
the People’s Republic of China. Notably, TB was the leading 
killer of people with HIV infection, accounting for about 
one-fifth of HIV deaths. In particular, an estimated 480,000 
people developed multidrug resistant (MDR)-TB globally 
in 2013, including 3.5% of new and 20.5% of previously 
treated TB cases (5% of total cases).5 There were ~210,000 
deaths from MDR-TB (range, 130,000–290,000). On aver-
age, an estimated 9% of people with MDR-TB have extensive 
MDR-TB (XDR-TB). Globally, the TB mortality rate fell 
by an estimated 45% between 1990 and 2013, and the TB 
prevalence rate fell by 41% during the same period.5
TB is most commonly transmitted from a person with 
infectious pulmonary TB to others by droplet nuclei, 
which are aerosolized by coughing, sneezing, or speaking.8 
M. tuberculosis normally enters into the pulmonary alveo-
lus via aerosol delivery of 2–5 μm particles, containing 
the bacterium. About one-third of the world’s population 
(~2 billion) is estimated to have been exposed to TB bacte-
ria and potentially infected.5 TB typically affects the lungs, 
but it also can affect any other organ of the body including 
lymph nodes, bones, kidneys, brain, spine, liver, skin, and 
intestine.9,10 WHO adopted the DOTS (Directly Observed 
Therapy, Short Course) strategy as the standard approach to 
address the global TB epidemic in 1993. The key component 
of the DOTS strategy recommended by WHO is the stan-
dard chemotherapy regimen for drug-susceptible TB, which 
requires continual oral administration of isoniazid (INH), 
rifampicin (RIF), pyrazinamide (PZA), and ethambutol 
(EMB) for 6 months. In the intensive phase, the treatment 
consists of 2 months of RIF, INH, PZA, and EMB, followed 
by 4 months of RIF and INH during the continuation phase.11 
In the continuation phase, EMB is added in countries with 
high levels of INH resistance in new TB patients, and in 
those where INH susceptibility testing in new patients is not 
conducted. The dosing frequency can be daily or 3 times/
week. Rifabutin (RBT) and rifapentine (RPT) may also be 
considered first-line drugs under certain circumstances.12,13 
RBT is used as a substitute for RIF in the treatment of all 
forms of TB caused by organisms that are known or presumed 
to be susceptible to this agent. RBT is generally reserved for 
patients for whom drug–drug interactions preclude the use 
of RIF. Streptomycin (SM) was formerly considered to be 
a first-line drug and is now used as a second-line anti-TB 
drug in the US due to increasing prevalence of resistance to 
SM. Other second-line anti-TB drugs approved by the US 
Food and Drug Administration (FDA) include cycloserine, 
capreomycin, ρ-aminosalicylic acid, and ethionamide. In 
the US, the FDA has approved fixed-dose combinations of 
150 mg INH and 300 mg RIF (Rifamate®, Sanofi-Aventis 
Pharmaceuticals, Bridgewater, NJ, USA) and of 50 mg INH, 
120 mg RIF, and 300 mg PZA (Rifater®, Sanofi-Aventis 
Pharmaceuticals). In view of the seriousness of TB infec-
tion, the People’s Republic of China established the China 
National Tuberculosis Prevention and Control Scheme in 
1990 and has been implementing DOTS since 1991, which 
constitutes the cornerstone of the current strategy for TB 
control and covers the country’s entire population.14 From 
1990 to 2010, the prevalence of smear-positive TB decreased 
from 170 to 59 cases/100,000 population in the People’s 
Republic of China.15 Although the treatment success rate 
is often more than 85% for newly diagnosed TB using the 
standard regimen, MDR-TB still develops in many patients 
due to resistance to INH and RIF.16–19 XDR-TB is a form of 
MDR-TB that responds to even fewer available medicines, 
including the most effective second-line anti-TB drugs.2,20,21 
MDR-TB is treated with a combination of second-line drugs 
including fluoroquinolones, aminoglycosides, ethionamide, 
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cycloserine, ρ-aminosalicyclic acid, linezolid, and clofaz-
imine for up to 2 years. Two new anti-TB drugs belonging to 
two novel classes of antibiotics have been recently approved: 
bedaquiline, by the FDA,22–24 and delamanid, by Japan and 
the European Union.25–28 These two drugs offer hope of better 
outcomes in severe cases of MDR-TB, but have not yet been 
tested to shorten treatment of drug-susceptible TB or as pre-
ventive treatment. Only 48% of the MDR-TB patients in the 
2011 cohort of detected cases were successfully treated, and 
the treatment success rate for XDR-TB patients in the 2011 
cohort was only 22% since second-line treatment options 
are limited and recommended medicines are not always 
available.20 Existing and newly approved anti-TB drugs 
are generally tolerated well by most patients, but they may 
cause side effects including liver injury, skin reactions, and 
gastrointestinal and neurological disorders in a proportion of 
patients that can be alleviated by symptomatic therapy.29–31 
Thus, there is a further need to develop highly effective and 
safe anti-TB drugs that can improve the clinical outcome and 
overcome multidrug resistance in the chemotherapy of TB.
To date, there has been increasing interest in the design 
and use of nanotechnology-based new delivery platforms 
with the potential for improving the efficacy and reduc-
ing the side effects associated with the treatment of newly 
diagnosed and MTD-TB.32–38 Many types of nanocarriers 
have been tested against TB, including vesicular drug 
delivery systems (liposomes, niosomes, and solid lipid 
nanoparticles), particulate drug delivery systems (nano-
particles, microparticles, and dendrimers), supramolecular 
drug delivery systems (polymeric micelles), specialized 
drug delivery systems (nanosuspensions, nanoemulsions, 
microemulsions, and dry powders), complex conjugate 
drug delivery systems (immunostimulating complex and 
cyclodextrin inclusion complexes), and other carrier-based 
drug delivery systems (eg, nanotubes, nanobeads, nanofi-
bers, quantum dots, etc).32,36,37 These nanometric delivery 
systems are expected to offer advantages over conventional 
systems by producing optimum effectiveness to the target 
site, enhanced therapeutic efficacy, uniform distribution of 
the drug throughout the target site, increased bioavailability 
and sustainability of anti-TB drugs, fewer side effects, and 
increased patient compliance. Nanoparticles as drug carri-
ers enable higher stability and carrier capacity along with 
immense improvement of drug bioavailability, which further 
leads to reduction in dosage frequency. Liposomes are safe 
and effective drug carriers and can be functionalized with a 
great variety of ligands for targeting. Importantly, the bilayer 
of liposomes can be utilized to combine both hydrophobic 
and hydrophilic drugs through self-assembling; liposomes 
are biodegradable with low cytotoxicity and immunogenic-
ity, and enter into mononuclear phagocytic macrophages 
preferentially.39–41
The host response to M. tuberculosis infection is complex 
and multifaceted, involving many components of the immune 
system, mainly the result of interplay between macrophages, 
T-cells, B cells, and neutrophils.42–49 The primary pathologic 
feature of M. tuberculosis infection is the formation of a 
granuloma.50 Macrophages are the main target of anti-TB drugs 
since they are the host of M. tuberculosis, and M. tuberculosis 
is internalized through phagocytosis by the resident alveolar 
macrophages.42–44,51,52 M. tuberculosis infection is an inflamma-
tory progress through the host immune system to release cytok-
ines and chemokines that stimulate and recruit a wide range of 
cells involved in immunity and inflammation.53,54 The actions 
of chemokines could be homeostatic, where they guide cells 
during immune surveillance for pathogens by interacting with 
antigen presenting cells residing in these tissues. Studies in mice 
and humans showed that interferon-γ (IFN-γ), tumor necrosis 
factor-α (TNF-α), and interleukin-12 (IL-12) are key cytokines 
involved in the control of M. tuberculosis infections.42–44,55 
Transforming growth factor-β1 (TGF-β1) primarily produced 
by mononuclear phagocytes is known as the immunoregula-
tory cytokines, inhibiting T-cell responses and deactivating 
the macrophages in patients with TB.51,56 Overexpression of 
TGF-β1 results in tissue damage and fibrosis in TB patients. In 
view of the key role of immune response in TB development, 
targeting the inflammatory response in TB may represent an 
effective approach to control TB.57 For example, silencing of 
TGF-β1 by small interfering RNA (siRNA) in macrophages 
results in a significant decrease in titers of the intracellular 
M. tuberculosis.58 siRNA can efficiently and specifically block 
the expression of homologous genes in vitro and in vivo when 
it promotes homologous mRNA degradation and induces cells 
to exhibit specific gene deletion phenotype. A recent study has 
shown that IL-1 confers host resistance through the induction 
of eicosanoids that limit excessive type I IFN production 
and foster bacterial containment.59 In TB-infected mice and 
patients, reduced IL-1 responses and/or excessive type I IFN 
induction are linked to an eicosanoid imbalance associated with 
disease exacerbation, while host-directed immunotherapy with 
clinically approved drugs that augment prostaglandin E
2
 levels 
prevents acute mortality of M. tuberculosis-infected mice.59 
These findings indicate that IL-1 and type I IFNs represent two 
major counter-regulatory classes of inflammatory cytokines 
that control the outcome of M. tuberculosis infection and are 
functionally linked via eicosanoids.
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Our previous studies have shown that an ultrashort-course 
chemotherapy regimen produced good efficacy and was 
well tolerated in spinal TB patients, with a mean duration of 
5.5 months.60–62 In the present study, we propose that a com-
bination of INH, RIF, PZA, SM, and TGF-β1 siRNA with the 
utilization of nanofabrication using liposomes can improve 
the anti-TB therapeutic effect and reduce the side effect in 
the treatment of TB. We aimed to synthesize multifunctional 
polyethylene glycosylated (PEGylated) liposomes that encap-
sulated four anti-TB drugs including SM, INH, RIF, and PZA 
linked to TGF-β1 siRNA to deliver the multifunctional lipo-
somes to human macrophages that were differentiated from 
the human leukemic (THP-1) cells. To explore the molecular 
targets, a quantitative proteomic study using stable isotope 
labeling with amino acids in cell culture (SILAC) was also 
conducted and the data initially validated.
Materials and methods
chemicals and reagents
INH, RIF, PZA, SM, phorbol 12-myristate 13-acetate 
(PMA), lipopolysaccharide (LPS), fetal bovine serum (FBS), 
ribonuclease A (RNase A), propidium iodide (PI), dimethyl 
sulfoxide (DMSO), and the primary antibody against human 
β-actin were purchased from Sigma-Aldrich Co. (St Louis, 
MO, USA). Cholesterol, 1,2-dioleoyl-3-trimethylammonium-
propane (DOTAP), high-performance liquid chromatography-
grade acetone, butanol, acetonitrile, thin-layer chromatography 
plates (1,000 and 200 mm), nuclear and cytoplasmic extraction 
reagent (NE-PER) kit, and Western blotting substrate were 
purchased from Thermo Fisher Scientific Inc. (Waltham, MA, 
USA). 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-
[amino(polyethylene glycol)-2000] (DSPE-PEG 2000) was 
purchased from Avanti Polar Lipids Inc. (Alabaster, AL, 
USA). The primers for the detection of TGF-β1, IL-1, IL-6, 
IL-8, TNF-α, and IFN-γ mRNAs, TGF-β1 siRNA, negative 
control siRNA, and primary antibody against human β-actin 
were obtained from Santa Cruz Biotechnology Inc. (Dallas, 
TX, USA). Roswell Park Memorial Institute (RPMI)-1640 
medium were obtained from Corning Cellgro Inc. (Herndon, 
VA, USA). Dulbecco’s phosphate buffered saline (PBS), 
thiazolyl blue tetrazolium bromide (MTT), and the annexin 
V: phycoerythrin (PE) apoptosis kit was purchased from 
BD Biosciences Inc. (San Jose, CA, USA). The Cyto-ID® 
autophagy detection kit was obtained from Enzo Life Sci-
ences Inc. (Farmingdale, NY, USA). Spectra/Por® Dialysis 
Membranes with molecular weight (MW) of 1,000 Da 
was purchased from Spectrum Laboratories Inc. (Rancho 
Dominguez, CA, USA). Polyvinylidene difluoride (PVDF) 
membrane was purchased from EMD Millipore Inc. (Bedford, 
MA, USA). Primary antibodies against human phosphorylated 
phosphoinositide 3-kinase (p-PI3K), phosphorylated p38 
mitogen-activated protein kinase (p-p38 MAPK), p38 
MAPK, mammalian target of rapamycin (mTOR), p-mTOR, 
phosphorylated extracellular signal-regulated kinase (ERK), 
p-ERK, phosphatase and tensin homologue (PTEN), beclin 1, 
microtubule-associated protein 1A/1B-light chain 3 (LC3), 
nuclear factor-κB (NF-κB), and nuclear factor (erythroid-
derived 2)-like 2 (Nrf2) were purchased from Cell Signaling 
Technology Inc. (Beverly, MA, USA). The kits for detecting 
human TGF-β1, IL-6, IL-8, TNF-α, and IFN-γ were purchased 
from eBioscience Inc. (San Diego, CA, USA).
cell culture
THP-1 cells were purchased from American Type Culture 
Collection (Manassas, VA, USA). The cells were main-
tained at 2×105 cells/mL, cultured in RPMI 1640 medium 
supplemented with 10% FBS, and incubated at 37°C in a 
5% CO
2
 humidified incubator. Medium renewal was carried 
out 2–3 times/week, and cells were subcultured when they 
achieved 80%–90% confluence. The THP-1 cells were dif-
ferentiated into macrophages by incubation with 100 ng/mL 
PMA for 48 hours in RPMI-1640 medium with 10% FBS, as 
described previously.63 After 48-hour treatment, suspended 
THP-1 cells were differentiated into adherent macrophages, 
the cells were washed with PBS three times, and suspended 
in fresh RPMI-1640 medium with 10% FBS for 3 hours.
chemical synthesis of Pegylated 
liposomes loaded with four anti-TB drugs 
and TgF-β1 sirna
The conjugation of sM to DsPe-Peg 2000
The nanoparticles were formulated using DSPE-PEG 2000 
and SM at a 1:10 molar ratio, which were dissolved in 2 mL 
DMSO, followed by adding 500 μL pyridine. The mixture 
was sonicated at 40°C for 2 hours, and then stirred at room 
temperature (RT) for 24 hours. The product was dialyzed in 
DMSO and then double deionized water (dd-H
2
O) to filter off 
the small molecule substances with MW less than 1,000 Da. 
Subsequently, the resultant product DSPE-PEG2000-SM 
was lipolyzed at -50°C.
Pegylated liposome formation and inh, riF,  
and PZa encapsulation
DOTAP, cholesterol, DSPE-PEG2000-SM, INH, RIF, and 
PZA were formulated in a 20:10:1:21:5.3:5.9 molar ratio and 
dissolved in chloroform (800 μL) and methanol (200 μL) 
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(4:1 v/v) after the self-assembly of the liposomal nanopar-
ticles. The organic solvent was evaporated under pressure 
gradually for 30 minutes at 30°C using a rotary evaporator. 
The resultant products were flushed with a stream of nitrogen 
gas to remove the residue of organic solvent. The products 
were stored in nitrogen gas at 4°C overnight.
cationic Pegylated liposomes with inh, riF,  
and PZa encapsulated TgF-β1 sirna
Cationic PEGylated liposome with INH, RIF, and PZA 
were codissolved in 500 μL DMSO and 500 μL RNase-free 
dd-H
2
O at RT. TGF-β1 siRNA was then added into the lipid 
film, and hydrated in a sonicated water bath for 1 minute, 
followed by filtration through a 0.20 μm Anotop 10 filter 
(Whatman, GE Healthcare Life Sciences, Little Chalfont, 
UK), which was incubated at RT for 30 minutes to allow it to 
be stabilized. The amount of TGF-β1 siRNA was formulated 
into cationic PEGylated liposomes at a 1:20 molar ratio for 
static neutralization with a final concentration of TGF-β1 
siRNA at 80 nM. The final liposomal complex (NP-siRNA) 
was maintained in a sterile environment for subsequent gene 
silencing experiments.
compound characterization by 
ultraviolet spectroscopy, fluorescent 
spectroscopy, and Fourier transform 
infrared spectroscopy
The instrument used for ultraviolet (UV) and fluorescent 
(FL) analysis was a BioTek microplate reader (Bio-Rad, 
Winooski, VT, USA). The software used for collecting the 
UV and FL data was the Gen5™. An Agilent Cary 630 FTIR 
(Fourier transform infrared) spectrometer (Agilent Technolo-
gies Inc., Santa Clara, CA, USA) was used for the IR spectra 
of the diamond module (solid) or transmission module.
scanning electron microscopy and 
transmission electron microscopy
The morphology of the novel anti-TB liposomes (NP-siRNA) 
were observed by scanning electron microscopy (SEM) 
(Hitachi High-Technologies Corp, Tokyo, Japan). Samples 
were prepared on stubs and coated with gold and palladium 
prior to examination. The morphology and size of the NP-
siRNA liposomes were also evaluated by transmission elec-
tron microscopy (TEM) (JEM 100CX; JEOL Ltd, Tokyo, 
Japan). An aqueous solution of liposomes was directly trickled 
onto a 300-mesh copper grid and dried in a vacuum oven at 
37°C for 4 hours, and the microimages were observed by 
TEM with an accelerating voltage of 80 kV. Meanwhile, the 
endocytosis of NP-siRNA liposomes by human macrophages 
was observed using TEM within 5 minutes at 4°C and 37°C 
as compared with the blank control without drug exposure.
size distribution and zeta potential 
measurement of the novel nP-sirna 
liposomes
The mean size and zeta potential of the liposomes were 
determined by dynamic light scattering using a zetasizer 1000 
HSA (Malvern Instruments, Malvern, UK). As a measure 
of particle size distribution of the dispersion, the system 
reported the polydispersity index (PDI) ranging from 0.0 for 
an entirely monodisperse sample up to 1.0 for a polydisperse 
liposomal mixture.
liquid chromatography mass 
spectrometry
The samples were cleaned and the concentration of anti-TB 
drugs analyzed by 6400 Series Triple Quadrupole LC/MS 
(Agilent Technologies Inc.) conducted on a Zorbax® Eclipse 
C
18
 column (Agilent Technologies Inc.) with a pore size of 
3.5 μm (4.6×100 mm). The analysis was conducted using a 
mobile phase consisting of acetonitrile and 0.1% formic acid in 
water, which was gradually increased from 20% to 80% over 
the course of the run at a flow rate of 1 mL/minute. The column 
was maintained at RT with an injection volume of 20 μL.
Drug release assay
The in vitro release profiles and kinetics of the novel NP-siRNA 
liposomes were determined by a dialysis method at various 
time points (0, 4, 8, 12, 24, 48, and 72 hours), as described 
previously by us.64 Briefly, 3 mL of the aqueous liposomes or 
corresponding parent drug was mixed with 1 mL PBS, and 
the mixture was dialyzed against water to filter off the small 
molecule substance with MW less than 1,000 Da. The resultant 
products were then dialyzed against 10 mL PBS containing 
10% FBS at 37°C with gentle shaking for 3 days. A 20 μL ali-
quot of the sample was withdrawn from the incubation medium 
and replaced with an equal volume of buffer at designated time 
points and stored frozen for further analysis. The released drugs 
were quantified by validated liquid chromatography mass spec-
trometry (LC–MS) methods. Calibration curves were prepared 
using different concentrations of individual free anti-TB drugs 
including INH, RIF, PZA, and SM.
cell viability assay
The MTT assays were performed to examine the effect of 
the novel NP-siRNA liposomes on cell viability of human 
Drug Design, Development and Therapy 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4446
niu et al
macrophages. THP-1 cells were seeded into 96-well plates at 
a density of 6,000 cells/well, which were differentiated into 
macrophages after treatment with PMA at 100 ng/mL for 
48 hours and maintained in RPMI medium. The macrophages 
were treated with a single anti-TB drug, a combination of 
four anti-TB drugs, or the multimodal NP-siRNA liposomes 
at concentrations of 2.5, 12.5, and 62.5 μg/mL, and then 
incubated for 24 hours at 37°C. Following the drug treat-
ment, 10 μL of MTT stock solution (5 mg/mL) was added 
to each well and incubated for 4 hours. Then, the medium 
was carefully removed, and 100 μL DMSO was added into 
each well. The plate was placed on a rocker to mix the solu-
tion thoroughly for 30 seconds, and incubated at 37°C for 
10 minutes. The absorbance was measured using a Synergy™ 
H4 Hybrid microplate reader (BioTek Inc, Winooski, VT, 
USA) at wavelengths of 560 and 670 nm. The 50% inhibitory 
potency (IC
50
) values were calculated from dose–response 
curves obtained in multireplicated experiments by GraphPad 
Prism 5 (GraphPad Software Inc., La Jolla, CA, USA).
cell cycle distribution analysis
The effect of the novel NP-siRNA liposomes on the cell 
cycle of macrophages was determined using PI as the DNA 
stain using flow cytometry, as described previously.65 Briefly, 
macrophages were treated with the novel NP-siRNA lipo-
somes at concentrations of 2.5, 12.5, and 62.5 μg/mL for 
24 hours at 37°C. Cells were trypsinized, washed by PBS, 
and suspended in 1 mL PBS containing 1 mg/mL RNase 
A and 50 μg/mL PI, fixed by 70% ethanol at -20°C over-
night. A total number of 1×105 cells were subject to cell 
cycle analysis using a flow cytometer (Becton Dickinson 
Immunocytometry Systems, San Jose, CA, USA). The flow 
cytometer collected 10,000 events.
Quantification of cellular apoptosis using 
flow cytometry
Annexin V is a 35–36 kDa Ca++-dependent phospholipid-
binding protein that has a high affinity for negatively charged 
phospholipid phosphatidylserine, and binds to cells that are 
actively undergoing apoptosis with exposed phospholipid 
phosphatidylserine. Apoptosis of human macrophages 
derived from THP-1 cells was quantitated using the BD 
Pharmingen™ annexin V:PE apoptosis detection kit (BD 
Biosciences Inc.) after cells were treated with the NP-
siRNA liposomes at different concentrations of 2.5, 12.5, 
and 62.5 μg/mL for 24 hours, as described previously.63,66,67 
Briefly, macrophages were trypsinized and washed with cold 
PBS. Following that, the cells were pelleted and resuspended 
in 1× binding buffer (BD Biosciences Inc.) with 5 μL of 
annexin V:PE and 5 μL of 7-aminoactinomycin D (7-AAD, 
a vital nucleic acid dye) at 1×105 cells/mL in a total volume 
of 100 μL. The cells were gently mixed and incubated in the 
dark for 15 minutes at RT. The sample was then mixed with 
150 μL 1× binding buffer and transferred into a clean test 
tube, and the number of apoptotic cells was quantified using 
the flow cytometer within 1 hour. Cells that stain positive for 
PE and annexin V, and negative for 7-AAD are undergoing 
apoptosis; cells that stain positive for PE, annexin V, and 
7-AAD are either in the end stage of apoptosis, are undergo-
ing necrosis, or are already dead; and cells that stain negative 
for PE annexin V and 7-AAD are alive and not undergoing 
measurable apoptosis.
Determination of autophagy of human 
macrophages by flow cytometry
The autophagy level in macrophages was examined using 
flow cytometry as described previously.67,68 THP-1-derived 
macrophages were treated with the novel NP-siRNA lipo-
somes at different concentrations of 2.5, 12.5, and 62.5 μg/mL 
for 24 hours. After 24-hour incubation, the cells were col-
lected and resuspended in a 250 μL phenol red-free culture 
medium containing 5% FBS. Following the resuspension, 
the cells were pelleted and 250 μL diluted Cyto-ID® (Enzo 
Life Sciences Inc.) Green stain solution was added to each 
sample and mixed well. Macrophages were incubated for 
30 minutes at 37°C in the dark. Then, the cells were col-
lected by centrifugation, washed with 1× assay buffer, and 
resuspended in 250 μL fresh 1× assay buffer. Cells were 
analyzed using the green (FL1) channel of the flow cytometer 
that collected 10,000 events.
Confocal fluorescence microscopy
Confocal fluorescence microscopy was performed to further 
examine the cellular autophagy using a Cyto-ID® (Enzo 
Life Sciences Inc.) autophagy detection kit according to the 
manufacturer’s instruction. The kit was used to measure cel-
lular autophagic vacuoles and autophagic flux using a novel 
dye that selectively labels autophagic vacuoles. The assay 
provides a rapid and quantitative approach to monitoring 
autophagy in live cells without the need for cell transfection, 
and allows the measurement and differentiation between 
autophagic flux and autophagolysosome accumulation. 
Briefly, THP-1-derived macrophages were seeded into an 
8-well chamber slide at 30% confluence for 24 hours. Then, 
the cells were treated with the NP-siRNA liposomes at 2.5, 
12.5, and 62.5 μg/mL for 24 hours. The confocal images 
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were recorded with a Leica TCS SP2 laser scanning confo-
cal microscope (Leica Microsystems, Wetzlar, Germany) at 
wavelengths of 405/488 nm.
enzyme-linked immunosorbent assay
Macrophages differentiated from THP-1 cells were treated 
with fresh medium alone (control), 0.1% DMSO, NP (the 
liposomes without TGF-β1 siRNA), NP-siRNA-control 
(the liposomes with control TGF-β1 siRNA), NP-siRNA 
liposomes with TGF-β1 siRNA linked, and the liposomes 
at a concentration of 12.5 μg/mL for 24 hours. A volume 
of 500 μL medium was collected at 24 hours and another 
500 μL fresh medium was supplemented. Cytokines includ-
ing TGF-β1, IL-6, IL-8, TNF-α, and IFN-γ in medium were 
quantified using ELISA (enzyme-linked immunosorbent 
assay) kits according to manufacturer’s protocol. LPS at a 
concentration of 100 ng/mL was added to the cell culture 
medium as a positive control.
Quantitative proteomic study using 
silac approach
Proteomic experiments were performed using SILAC 
protein quantitation kits from Thermo Fisher Scientific 
Inc., as described previously by us.69,70 Briefly, THP-1 
cells were cultured in the medium with (heavy) or 
without (light) stable isotope labeled amino acids (13C
6
 
l-lysine and 13C
6
 15N
4
 l-arginine). THP-1 cells were 
passaged for five times by changing the medium or 
splitting the cells. THP-1 cells were differentiated into 
macrophages by treatment with 100 ng/mL PMA for 48 
hours. Then, macrophages were treated with the novel 
NP-siRNA liposomes at a concentration of 12.5 μg/mL 
for 24 hours, which were maintained in heavy medium. 
Following that, the cells were harvested and lysated with 
hot lysis buffer (100 mM Tris base, 4% sodium dodecyl 
sulfate [SDS], and 100 mM dithiothreitol). The protein 
was denatured at 95°C for 5 minutes and sonicated at 20% 
amplitude for 3 seconds with 6 pulses. The samples were 
centrifuged at 15,000× g for 20 minutes, and the supernatant 
was collected in clean tubes. The protein concentration was 
determined using the ionic detergent compatibility reagent 
from Thermo Fisher Scientific Inc. Subsequently, equal 
amounts of heavy and light protein samples were combined 
to reach a total volume of 30–60 μL containing 300–600 μg 
protein. The combined protein sample was digested using 
FASP™ protein digestion kit from Protein Discovery Inc. 
(Knoxville, TN, USA). After the protein was digested, the 
resultant sample was acidified to pH 3.0 and desalted using 
a C
18
 solid-phase extraction column. The protein IDs were 
identified using Scaffold 4.3.2 from Proteome Software 
Inc. (Portland, OR, USA), and the pathway was analyzed 
using Ingenuity Pathway Analysis (IPA) from QIAGEN 
(Redwood City, CA, USA).
Western blotting analysis
The levels of various cellular proteins were determined using 
Western blotting assays as described previously.65 Mac-
rophages were washed with PBS after 24-hour treatment with 
0.1% DMSO, NP, NP-siRNA-control, and NP-siRNA, lysed 
with the radioimmunoprecipitation assay buffer (50 mM 
4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid 
[HEPES] at pH 7.5, 150 mM NaCl, 10% glycerol, 1.5 mM 
MgCl
2
, 1% Triton-X 100, 1 mM ethylenediaminetetraacetic 
acid [EDTA] at pH 8.0, 10 mM sodium pyrophosphate, and 
10 mM sodium fluoride) containing the protease inhibitor 
and phosphatase inhibitor cocktails. Nuclear–cytoplasmic 
fractionation was conducted using the NE-PER kit accord-
ing to the manufacturer’s protocol. Protein concentrations 
were determined using the bicinchoninic acid assay kit 
from Thermal Fisher Scientific Inc. An equal amount of 
protein sample was electrophoresed on 7%–12% SDS poly-
acrylamide gel electrophoresis (SDS–PAGE) mini-gel after 
thermal denaturation for 5 minutes at 95°C. Proteins were 
transferred onto immobilon PVDF membrane at 400 mA 
for 2 hours at 4°C. Membranes were probed with indicated 
primary antibody overnight at 4°C and then blotted with 
secondary antibody. Visualization was performed using the 
Bio-Rad ChemiDoc™ XRS system (Hercules, CA, USA) 
with an electrochemiluminescent substrate. The blots were 
analyzed using Image Lab 3.0 (Bio-Rad Inc.). Protein level 
was normalized to the matching densitometric value of the 
internal control β-actin.
Quantitative real-time polymerase chain 
reaction (rT-Pcr) assay
The THP1-derived macrophages were treated with dif-
ferent drugs for 6 hours, and total RNA was extracted by 
TRIzol® reagent and single-strand cDNA synthesized by a 
high-capacity cDNA reverse transcription kit (Invitrogen 
Inc., Carlsbad, CA, USA). The quality of the RNA was 
examined by determining the 260/280 absorbance ratio 
using a GeneQuant™ Pro spectrophotometer (Amersham 
Pharmacia Biotech Inc., Arlington Heights, IL, USA). The 
reaction was performed in triplicate in a total volume of 
10 μL QuantiTest™ SYBR® Green PCR Kit (Qiagen Inc., 
Valencia, CA, USA), 2 μL cDNA, 2 μL each of the primers, 
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and 6 μL RNase-free water on a 7500 Fast Real-Time PCR 
System (Applied Biosystems) according to the manufacturer’s 
instructions. The PCR reaction condition was 95°C for 3 min-
utes, followed by 40 cycles at 95°C for 15 seconds, and 60°C 
for 60 seconds. Gene expression levels were analyzed using 
the comparative Ct method (2-ΔΔCt) with glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as the normalizer.
statistical analysis
All experiments were performed in triplicate, with the results 
presented from representative experiments. Data are presented 
as the mean ± standard deviation (SD). Multiple compari-
sons were analyzed by one- or two-way analysis of variance 
(ANOVA). Differences between two groups were analyzed 
using unpaired Student’s t-test. Statistical difference was con-
sidered significant at P0.05. Statistical probability is indi-
cated as follows: *P0.05; **P0.01; and ***P0.001.
Results
synthesis of the novel nP-sirna 
liposomes
SM (Figure 1A) was conjugated to the amino terminals of the 
PEG segment in DOTAP to obtain the polymerized SM. The 
SM-PEG was then dialyzed against DMSO and dd-H
2
O alter-
natively to remove the free drugs with MW cutoff at 3,000 Da. 
The physicochemical properties of the synthesized particles 
were characterized by the UV, FL, and FTIR spectroscopy. 
UV and FL spectra showed characteristic absorption peaks 
for the SM conjugation (Figure 1A–C). With regard to the UV 
spectra, the extreme absorption at 320 nm for SM, it preserved 
the same extreme at 320 nm after the conjugation (Figure 1A)
. 
In the FL spectrum, SM showed a maximum peak at E
m
 of 
450 nm when excited at 390 nm, while the conjugated SM 
displayed a maximum peak at E
m
 of 450 nm as well, which 
was absent for the un-functionalized polymer (Figure 1B).
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Figure 1 representative spectra of sM, Peg, sM-Peg, DMsO, and dd-h2O.
Notes: representative UV and chemical structure of sM (A), Fl (B), and FTir (C) spectra for sM, Peg, sM-Peg, DMsO, and dd-h2O. FTir shows sM-Peg formed by 
the -Oh of sM connected with -nh2 of Peg. arrow 1 shows the spectral peaks of Peg, and arrow 2 points to the spectral peaks of sM.
Abbreviations: dd-h2O, distilled deionized water; DMSO, dimethyl sulfoxide; FL, fluorescence; FTIR, Fourier transform infrared spectroscopy; PEG, polyethylene glycol; 
sM, streptomycin; UV, ultraviolet.
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In FTIR spectra of SM-PEG, the successful conjugation 
was indicated by the –OH groups of the sugar structures 
of SM (Figure 1C).
 
In addition, the absorption peak at 
3,385 cm-1 of SM-PEG showed characteristic PEG residue 
for the O–H bending vibration, which confirmed a success-
ful conjugation of SM with PEG. Additionally, the peak at 
1,538 cm-1 of SM-PEG represented the stretching vibration 
of C=N of SM.
Finally, the liposomes were formulated through a self-
assembly process with DOTAP, cholesterol, chloroform, 
methanol, and encapsulated anti-TB drugs including INH, 
RIF, and PZA, and SM-PEG to form cationic PEGylated 
liposomes. The TGF-β1 siRNA was linked to the cationic 
PEGylated liposomes via the electrostatic interaction.
Particle size and morphology of the novel 
liposomal nanoparticles
The morphology and size distribution of the novel NP-siRNA 
liposomes were examined using SEM (Figure 2A) and TEM 
(Figure 2B). The morphology of the NP-siRNA liposomes 
was spherical with double layers encapsulated, compared 
with the randomly orientated PEG particles (Figure 2C).
The internalization of the NP-siRNA liposomes to the 
macrophages had been examined using TEM. The mac-
rophages were observed without drug exposure under TEM 
(Figure 2D). The novel NP-siRNA liposomes at 12.5 μg/mL 
was endocytosed by macrophages at 37°C after drug exposure 
for 5 minutes (Figure 2E and F), whereas this process could 
not be duplicated at 4°C (Figure 2G).
Finally, the mean size and zeta potential were measured 
using a Malvern Zeta Nanosizer ZS 90 (Malvern Instru-
ments). The zeta potential of TGF-β1 siRNA was -12.71 kV, 
which represented the stability of the liposomal formulation. 
The mean size of the nanoparticles was 265.1 nm with a PDI 
of 0.290 and zeta potential of 31.8 kV (Figure 3).
The release profile in vitro of the 
liposomal nanoparticles
The release profiles of the anti-TB drugs from the NP-siRNA 
liposomes are shown in Figure 4. The amounts of the anti-TB 
drugs released from the NP-siRNA liposomes were quantified 
using validated LC–MS methods. Figure 4A–D show the drug 
release profiles for the liposomal nanoparticles and free INH, 
RIF, PZA, and SM over 72 hours. Overall, the encapsulated 
anti-TB drugs were released from the novel NP-siRNA lipo-
somes in a sustained manner for up to 48 hours (Figure 4A–D). 
However, the free anti-TB drugs were released in a burst 
between 8 and 12 hours, and most of the drugs were signifi-
cantly released after 24 hours (Figure 4A–D).
As shown in Figure 4A, the free INH exhibited a faster 
release than that of the novel NP-siRNA liposomes with 
an 8.2- and 3.7-fold change at the time points of 4 and 
8 hours, respectively (P0.001). In contrast, the novel NP-
siRNA liposomes showed a sustainable releasing prolife 
for INH, and the novel NP-siRNA liposomes released 1.5, 
2.5, and 4.8 times higher concentrations of INH than that of 
the free INH at time points of 24, 48, and 72 hours, respec-
tively (P0.001; Figure 4A). Similarly, free RIF showed 
a faster release profile than that of the novel NP-siRNA 
liposomes with a 1.5- and 1.6-fold change at time points 
of 8 and 12 hours, respectively (P0.001; Figure 4B). 
In contrast, the novel NP-siRNA liposomes exhibited 2.4, 
4.0, and 5.3 times higher concentrations of RIF than that 
of the free RIF at the time points of 24, 48, and 72 hours, 
respectively (P0.001; Figure 4B). As shown in Figure 4C, 
the concentration of PZA was 1.5 times higher in the free 
PZA than that of the novel NP-siRNA liposomes at the time 
point of 8 hours (P0.001), whereas the concentrations 
of PZA were 3.3, 8.5, and 13.7 times higher in the novel 
NP-siRNA liposomes than that of the free PZA at the time 
points of 24, 48, and 72 hours, respectively (P0.001; 
Figure 4C).
In addition, SM showed a similar release profile as 
INH, RIF, and PZA in free SM and the novel NP-siRNA 
liposomes (Figure 4C). The concentrations of SM were 
5.6 and 2.6 times higher for free SM than that of the novel 
NP-siRNA liposomes at the time points of 8 and 12 hours, 
respectively (P0.001), whereas the concentrations of 
SM were 1.4, 5.7, and 15.0 times higher in the novel 
NP-siRNA liposomes than that of the free SM at the time 
points of 24, 48, and 72 hours, respectively (P0.001; 
Figure 4D).
cytotoxicity of the novel nP-sirna 
liposomal nanoparticles in ThP-1-derived 
macrophages
The cytotoxicity of the NP-siRNA liposomal nanoparticles 
on human macrophages differentiated from THP-1 cells 
was examined using the MTT assay. The IC
50
 value in 
24 hours of the novel NP-siRNA liposomes was 269.5 μg/mL 
(Figure 5A). When the four anti-TB drugs were used in com-
bination, the IC
50
 value was 241.8 μg/mL, which was lower 
than individual free anti-TB drugs (Figure 5B). In addition, 
the IC
50
 values for INH, RIF, PZA, and SM were 92.55, 
132.5, 144.0, and 79.96 μM, respectively (Figure 5C−F). 
Collectively, the newly synthesized anti-TB liposomes 
showed a lower cytotoxicity in comparison with the anti-TB 
drugs in combination.
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Figure 2 The morphology of newly synthesized nP-sirna liposomes under seM and TeM.
Notes: (A) seM images showing the round shapes of newly synthesized nP-sirna liposomes. (B) TeM images showing the spherical shapes of the newly synthesized nP-
sirna liposomes. (C) TeM images showing the irregular shapes of Peg. (D) TeM images showing the macrophages without exposure to the nP-sirna liposomes. (E) TeM 
images showing the endocytosis of nP-sirna liposomes by macrophages at 37°c. (F) TeM images showing the endocytosed nP-sirna liposomes in macrophages at 37°c. 
(G) TeM images showing lack of endocytosis of nP-sirna liposomes by macrophages at 4°c. arrows point to nP-sirna liposomal nanoparticles.
Abbreviations: nP, nanoparticle; Peg, polyethylene glycol; seM, scanning electron microscopy; sirna, small interfering rna; TeM, transmission electron microscopy.
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Figure 3 The size distribution of the novel nP-sirna liposomes.
Notes: The size and the zeta potential of the novel nP-sirna liposomes were 
measured using a Malvern Zeta nanosizer Zs 90. The peak size of the novel nP-
sirna liposomes was 265.1 nm with a PDi of 0.290 and zeta potential was 31.8 mV.
Abbreviations: nP, nanoparticle; PDi, polydispersity index; sirna, small 
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Figure 4 Drug release profiles of NP-siRNA liposomes containing the anti-TB drugs and free antidrugs determined by a dialysis method.
Notes: (A) The drug release profile of liposomes and free INH over 72 hours. (B) The drug release profile of liposomes and free RIF over 72 hours. (C) The drug release 
profile of liposomes and free PZA over 72 hours. (D) The drug release profile of liposomes and free SM over 72 hours. Drug concentrations are measured by validated 
lc–Ms methods. Data are the mean ± sD of three independent experiments. Data were analyzed by two-way anOVa. statistical probability is indicated as follows: 
**P0.01; ***P0.001 by two-way anOVa.
Abbreviations: anOVa, analysis of variance; inh, isoniazid; lc–Ms, liquid chromatography mass spectrometry; nP, nanoparticle; PZa, pyrazinamide; riF, rifampicin; 
sD, standard deviation; sirna, small interfering rna; sM, streptomycin; TB, tuberculosis.
were examined using flow cytometry. The results showed 
there was no significant difference in the percentage of 
cell populations in G
1
, S, and G
2
/M phases when the mac-
rophages were treated with the novel NP-siRNA liposomes 
at concentrations of 2.5, 12.5, and 62.5 μg/mL (Figure 6A 
and B). In order to measure the apoptosis-inducing effect 
of the novel NP-siRNA liposomal nanoparticles in THP-1-
derived macrophages, the number of apoptotic macrophages 
was quantified using flow cytometry. As shown in Figure 6C 
and D, no significant apoptosis-inducing effect of NP-siRNA 
liposomes was observed in human macrophages.
We also examined the effect of the novel NP-siRNA 
liposomes on autophagy in THP-1-derived macrophages 
using flow cytometry (Figure 6E and F) and confocal 
fluorescence microscopy (Figure 6G and H). Notably, 
treatment of macrophages with 62.5 μg/mL NP-siRNA 
liposomes for 24 hours remarkably increased the percent-
age of autophagic cells 7.5-fold (P0.001; Figure 6F), 
which was consistent with confocal microscopic results 
when compared with the control cells (2.5-fold; P0.001; 
Figure 6H).
effects of the nP-sirna liposomal 
nanoparticles on cell cycle distribution, 
apoptosis, and autophagy in ThP-1-
derived macrophages
The effects of the novel NP-siRNA liposomal nanoparticles 
on cell cycle distribution in THP-1-derived macrophages 
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Figure 5 cytotoxicity of the novel nP-sirna liposomes and free anti-TB drugs toward ThP-1-derived macrophages determined by the MTT assay.
Notes: cells were cultured and treated with nP-sirna liposomes or the anti-TB drugs for 24 hours. The ic50 values were determined and compared. (A) survival of 
ThP-1-derived macrophages treated with 2.5-1,000 μg/ml nP-sirna liposomes for 24 hours. (B) survival of ThP-1-derived macrophages treated with 2.5-200 μg/ml 
combined anti-TB drugs including inh, riF, PZa, and sM for 24 hours. (C) survival of ThP-1-derived macrophages treated with 0.1-100 μM inh for 24 hours. (D) survival 
of ThP-1-derived macrophages treated with 1-100 μM riF for 24 hours. (E) survival of ThP-1-derived macrophages treated with 1-100 μM PZa for 24 hours. (F) survival 
of ThP-1-derived macrophages treated with 0.1-100 μM sM for 24 hours. Data are the mean ± sD of three independent experiments.
Abbreviations: inh, isoniazid; MTT, thiazolyl blue tetrazolium bromide; nP, nanoparticle; PZa, pyrazinamide; riF, rifampicin; sD, standard deviation; sirna, small 
interfering rna; sM, streptomycin; TB, tuberculosis.
Next, we investigated the underlying mechanisms for the 
autophagy-inducing effect of the novel NP-siRNA liposomes 
in macrophages. First, we examined the phosphorylation lev-
els of PI3K at Tyr199, and p38 MAPK at Thr180/Tyr182 that 
are upstream signaling molecules of Akt/mTOR pathway and 
play important roles in the regulation of cell proliferation and 
death (Figure 7A). In this study, exposure of macrophages 
to 2.5, 12.5, and 62.5 μg/mL NP-siRNA liposomes for 
24 hours did not significantly affect the phosphorylation 
level of p-PI3K at Tyr 199 (Figure 7B). However, treatment 
of macrophages with 62.5 μg/mL NP-siRNA liposomes for 
24 hours reduced the phosphorylation level p38 MAPK at 
Thr180/Tyr182. p38 MAPK has bifurcated roles in the regu-
lation of cell fate: it can either mediate cell survival or cell 
death, depending not only on the type of stimulus but also in 
a cell type specific manner.71,72 In comparison with the control 
cells, the phosphorylation level of p38 MAPK and the ratio 
of p-p38 MAPK/p38 MAPK were decreased 15.8% when 
cells were treated with NP-siRNA liposomes at 62.5 μg/mL 
(P0.05; Figure 7A and B). mTOR plays a key role in cell 
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Figure 6 effects of the novel nP-sirna liposomes on cell cycle distribution, apoptosis, and autophagy in ThP-1-derived macrophages.
Notes: cells were treated with the novel nP-sirna liposomes at 2.5, 12.5, and 62.5 μg/ml for 24 hours, and the effects on cell cycle distribution, apoptosis, and autophagy 
in macrophages were examined using flow cytometry and confocal microscopy. (A) Representative DNA fluorescence histograms show the effect of treatment with 
nP-sirna liposomes on cell cycle distribution. (B) Bar graphs show the percentage of macrophages in g1, s, and g2/M phases. (C) Representative flow cytometric dot plots 
show the distribution of macrophages undergoing early or late apoptosis when treated with the nP-sirna liposomes at 2.5, 12.5, and 62.5 μg/ml for 24 hours. (D) Bar 
graphs show the percentage of macrophages undergoing early or late apoptosis when treated with the nP-sirna liposomes at 2.5, 12.5, and 62.5 μg/ml for 24 hours. (E) 
Representative flow cytometric dot plots show the autophagic cells when treated with the NP-siRNA liposomes at 2.5, 12.5, and 62.5 μg/ml for 24 hours. (F) Bar graphs show 
the percentage of autophagic macrophages when the cells were treated with the nP-sirna liposomes at 2.5, 12.5, and 62.5 μg/ml for 24 hours. (G) The confocal microscopic 
images show the cyto-iD® stained autophagic cells with green fluorescence when the cells were treated with the NP-siRNA liposomes at 2.5, 12.5, and 62.5 μg/ml for 24 
hours. (H) Bar graphs show the fluorescence level, reflecting the level of autophagic macrophages when the cells were treated with the NP-siRNA liposomes at 2.5, 12.5, and 
62.5 μg/ml for 24 hours. Data are present as the mean ± sD of three independent experiments. ***P0.001 by one-way anOVa followed by Tukey’s post hoc test. 
Abbreviations: anOVa, analysis of variance; nP, nanoparticle; sD, standard deviation; sirna, small interfering rna.
growth, autophagic cell death, and homeostasis. Exposure 
of cells to 62.5 μg/mL NP-siRNA liposomes resulted in a 
38.3% decrease in the ratio of p-mTOR/mTOR at Ser2448 
(Figure 7A).
PTEN, a dual-specificity phosphatase and tumor suppres-
sor gene, inhibits Akt/mTOR and MAPK signaling pathways, 
leading to cell death and growth regulation.73 Autophagy is 
tightly regulated by beclin 1 (a mammalian homologue 
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Figure 7 effects of the novel nP-sirna liposomes on the expression levels of pro- and antiautophagic proteins in ThP-1-derived macrophages determined by Western 
blotting assay.
Notes: (A) representive blots of p-Pi3K, p-mTOr, mTOr, p-p38 MaPK, p38 MaPK, PTen, beclin 1, and lc3 in macrophages treated with the nP-sirna liposomes at 2.5, 
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Drug Design, Development and Therapy 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4456
niu et al
of yeast Atg6) that forms a complex with vacuolar sort-
ing protein 34, and serves as a platform for recruitment of 
other Atgs that are critical for autophagosome formation.74 
LC3, a mammalian homologue of yeast Atg8, is associated 
with the autophagosome membranes after processing and 
has been used as a specific marker monitor autophagy.75,76 
In comparison with the control cells, the expression levels 
of PTEN, beclin 1, and LC3 increased 1.3-, 1.5-, and 1.6-
fold when treated with 62.5 μg/mL NP-siRNA liposomes, 
respectively (P0.05; Figure 7A and B), whereas there was 
no significant alteration in the expression levels of PTEN, 
beclin 1, and LC3 in macrophages with the treatment of 2.5 
and 12.5 μg/mL novel NP-siRNA liposomes for 24 hours 
(Figure 7A and B).
effects of the novel nP-sirna liposomal 
nanoparticles on the expression levels 
of TgF-β1, il-6, il-8, TnF-α, and iFn-γ 
in ThP-1-derived macrophages
TGF-β1, IL-6, IL-8, TNF-α, and IFN-γ can be secreted by 
macrophages. We examined whether the novel NP-siRNA 
liposomes were able to decrease the expression levels of 
TGF-β1, IL-6, IL-8, TNF-α, and IFN-γ. The ELISA results 
showed the expression level of TGF-β1 in supernatants 
obtained from macrophages culture medium was decreased 
in macrophages treated with the novel NP-siRNA lipo-
somes at 12.5 μg/mL for 24 hours, whereas the level of 
TFG-β1 was not significantly altered in control, DMSO, 
NP, NP–siRNA-control groups (Figure 8). LPS treatment 
increased the level of TGF-β1. Moreover, the expres-
sion levels of IL-6, IL-8, TNF-α, and IFN-γ (Figure 8) 
in NP-siRNA treated cells were elevated compared with 
blank control.
effects of the novel nP-sirna liposomes 
on the mrna levels of TGF-β1, IL-1, IL-6, 
IL-8, TNF-α, and IFN-γ in ThP-1-derived 
macrophages
Furthermore, the mRNA expression levels of key cytokines 
were assessed in THP-1-derived macrophages treated with 
NP-siRNA liposomes by RT-PCR. The expression level of 
TGF-β1 mRNA was markedly decreased in the macrophages 
after treatment with NP-siRNA compared with the controls 
(Figure 9). In contrast, TNF-α and IFN-γ  mRNA expression 
levels were increased in macrophages (Figure 9), whereas 
there was no significant difference in the expression levels 
of IL-1, IL-6, and IL-8 mRNA (Figure 9).
Proteomic responses to nP-sirna 
liposome treatment in ThP-1-derived 
macrophages
In order to reveal the proteomic responses to NP-siRNA 
liposomes in THP-1-derived macrophages, a SILAC-based 
quantitative proteomic study was conducted to determine 
the molecular targets of NP-siRNA liposomes. Our study 
showed that there were numerous molecules and signaling 
pathways that responded to NP-siRNA liposome treatment 
(Figure 10A and B, Tables 1–3).
The IPA data showed that there were over 40 signaling 
pathways involved in the proteomic responses to NP-siRNA 
liposome exposure in human macrophages, with 160 proteins 
mapped (Figure 10A and B). The top five canonical signaling 
pathways were eukaryotic initiation factor 2 (EIF2) signaling 
(Figure 11), actin cytoskeleton signaling, remodeling of 
epithelial adherens junctions, epithelial adherens junction 
signaling, and Rho GDP-dissociation inhibitor (RhoGDI) 
signaling pathways (Table 1). Of note, treatment of mac-
rophages with NP-siRNA liposomes regulated programmed 
cell death pathways including apoptosis and PI3K/Akt/
mTOR signaling pathways (Figure 10A and B). We further 
studied the EIF2 signaling pathway and found that the expres-
sion level of ERK1/2, the key protein involved in the EIF2 
signaling pathway, was increased (Figure 11). Futhermore, 
the IPA data presented that ERK1/2 played a pivotal role 
in the ERK/MAPK signaling pathway. Treatment of mac-
rophages with the novel NP-siRNA liposome increased the 
expression level of ERK1/2, which in turn enhanced a number 
of gene transcriptions in the nucleus (Figure 12). Of note, 
the IPA results showed that NF-κB, PI3K, and heat shock 
protein 90 (HSP90) were involved in the ERK1/2 signal-
ing pathway in response to the novel NP-siRNA liposome 
treatment, which may contribute to the immune response, 
control of viral gene expression, antiapoptosis, antiviral 
response, and antimicrobial response (Figure 13) and cell 
growth (Figure 14).
ERK1/2 has a crucial role in the regulation of cellular 
processes, including cell cycle progression, cell proliferation 
and differentiation, cytokine generation, gene transcription, 
cell migration and invasion, senescence, cell death, GAP 
junction formation, actin and microtubule networks, and 
neurite extension.77 Aberrations in ERK1/2 signaling have 
been implicated in many pathologies including many cancers, 
diabetes, and infectious and cardiovascular diseases.78 
Thus, we analyzed the ERK signaling pathways, and the 
upstream regulators are given in Table 2, in which TGF-β1 
was involved. Then, we further detected the upregulated 
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Figure 8 effects of the novel nP-sirna liposomes on the expression levels of TgF-β1, il-6, il-8, TnF-α, and iFn-γ in ThP-1-derived macrophages determined by elisa.
Notes: Macrophages were cultured and treated with 12.5 μg/ml nP-sirna liposomes, DMsO, nP-sirna-control or medium for 24 hours. The levels of cytokines were 
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and downregulated genes involved in the TGF-β1-mediated 
signaling pathways (Table 3).
The subsequent validation experiments showed that the 
phosphorylation level of ERK1/2 was increased 1.2- and 
1.3-fold in human macrophages with the treatment of NP-
siRNA-control and NP-siRNA liposomes at 12.5 μg/mL for 
24 hours, respectively (P0.05 or 0.01; Figure 15A and B). 
However, there was no significant alteration in the expression 
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Figure 10 The proteomic profiling of human macrophages treated with the novel NP-siRNA liposomes at 12.5 μg/ml for 24 hours determined using silac.
Notes: The proteomic responses of macrophages to NP-siRNA were examined using SILAC, and the pathways were analzyed by IPA. This figure shows the top pathways 
from the proteomic study with the threshold of 1.2 of –log(P-value) (A and B).
Abbreviations: iPa, ingenuity pathway analysis; nP, nanoparticle; silac, stable isotope labeling with amino acids in cell culture; sirna, small interfering rna.
level of ERK1/2 in control cells (Figure 15A and B). There 
was a 49.2% decrease in the expression level of NF-κB in 
the macrophages when treated with the novel NP-siRNA 
liposomes at 12.5 μg/mL for 24 hours, whereas there was 
no marked change in the expression level of NF-κB in mac-
rophages with the treatment of NP and NP-siRNA-control 
(P0.01; Figure 15A and B). Of note, in comparison with the 
NP treatment group, NP-siRNA liposomes decreased 55.9% 
in the expression level of NF-κB (P0.001; Figure 15A 
and B). In contrast, the level of Nrf2 was remarkably 
increased 1.4- and 1.6-fold in human macrophages with the 
treatment of NP-siRNA-control and NP-siRNA liposomes at 
12.5 μg/mL for 24 hours, respectively (P0.05; Figure 15A 
and B). Taken together, NF-κB plays a critical role in the 
siRNA-mediated therapy targeting the TGF-β1 inflammatory 
signaling pathway in the treatment of TB.
Drug Design, Development and Therapy 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
4460
niu et al
Table 1 The top five canonical signaling pathways regulated by the 
novel nP-sirna liposomes in ThP-1-derived in macrophages
Pathway P-value Ratio
eiF2 signaling 2.93×10-9 9/201 (0.045)
actin cytoskeleton signaling 1.90×10-7 8/242 (0.033)
remodeling of epithelial adherens junctions 1.61×10-6 5/70 (0.071)
epithelial adherens junction signaling 4.19×10-6 6/154 (0.039)
rhogDi signaling 1.15×10-5 6/202 (0.030)
Note: Data in the parenthesis shows the ratio of regulated proteins over the total 
proteins in the targeted signaling pathway.
Abbreviations: eiF2, eukaryotic initiation factor 2; rhogDi, rho gDP-dissociation 
inhibitor.
Table 2 The top eleven upstream proteins regulated by the novel 
nP-sirna liposomes in ThP-1-derived macrophages
Upstream  
regulator
P-value  
of overlap
Predicted  
activation state
aPP 5.87×10-17
cD3 4.90×10-3 inhibited
cD437 1.50×10-5 inhibited
hsF1 3.89×10-6 inhibited
MaPT 1.90×10-18
MYc 2.30×10-12 activated
MYcn 1.16×10-12 activated
Psen1 1.40×10-15
sirolimus 3.77×10-11 inhibited
TgF-β1 4.82×10-5
TnF-α 1.27×10-4
Abbreviations: aPP, β-amyloid (a4) precursor protein; cD3, T-cell surface glyco-
protein; cD437, a cell-permeable, selective agonist of retinoic acid receptor; hsF1, 
heat shock transcription factor 1; MaPT, microtubule-associated protein tau; MYc, 
v-myc avian myelocytomatosis viral oncogene homologue; MYcn, v-myc avian myelo-
cytomatosis viral oncogene neuroblastoma derived homologue; Psen1, presenilin 1; 
TgF-β1, transforming growth factor-β1; TnF-α, tumor necrosis factor-α.
effects of the nP-sirna liposomes 
on nF-κB production in ThP-1-derived 
macrophages
The interplay between TGF-β1 and NF-κB is involved in the 
inflammatory response to M. tuberculosis infection; TGF-β1 
is involved in the TB growth by activating the NF-κB, which 
in turn reactivates TGF-β1 and other cytokine pathways 
in macrophages.42–44,51,58 Thus, we examined the effect of 
NP-siRNA liposomes on the expression of NF-κB in THP-1
-derived macrophages. As shown in Figure 15C and D, there 
was a remarkable decrease in the expression level of NF-κB 
when treated with NP-siRNA liposomes in THP1-derived 
macrophages. There was a reduction of 18.0%, 15.2%, and 
44.0% in the expression levels of NF-κB in macrophages 
treated with NP-siRNA liposomes at 2.5, 12.5, and 62.5 μg/
mL, respectively (P0.05 or 0.001; Figure 15D). Moreover, in 
comparison with cells treated with DMSO, NP, or NP-siRNA-
control, the NP-siRNA liposomes exhibited a potent inhibi-
tory effect on the expression of NF-κB, and the 62.5 μg/mL 
NP-siRNA liposomes exerted a maximum suppressing effect 
on NF-κB expression in macrophages (Figure 15A and B). 
Collectively, the results show that NP-siRNA liposomes 
suppress the expression of NF-κB, probably contributing 
to the attenuated inflammatory response to M. tuberculosis 
infection.
Discussion
The majority of infected individuals develop asymptomatic 
latent TB, while ~5%–10% of latently infected individuals 
will progress to active pulmonary TB.79,80 Due to the poor 
compliance, drug resistance, and potential side effects of 
the current chemotherapy for TB treatment, TB remains 
the second leading cause of mortality worldwide due to a 
single infectious agent, resulting in a substantial burden on 
individuals and the healthcare system. Therefore, it requires 
new approaches and therapies to achieve a better therapeutic 
effect and minimal side effects for the treatment of TB. With 
the development of new therapeutic drugs and/or novel drug 
delivery systems for TB treatment, it is expected to improve 
therapeutic effect and reduce side effects in clinical practice. 
In this study, we have synthesized and characterized the 
multifunctional PEGylated liposomes that encapsulated 
four anti-TB drugs including SM, INH, RIF, and PZA and 
linked to TGF-β1 siRNA. The newly synthesized NP-siRNA 
liposomes exhibit favorable physicochemical and biologi-
cal properties in THP-1 differentiated macrophages. Our 
results show that human macrophages can engulf the novel 
NP-siRNA liposomes. Of importance, our SILAC-based 
quantitative proteomic study has revealed specific proteomic 
responses to the treatment of the novel NP-siRNA liposomes 
in human macrophages, and the initial validation experiments 
verify the involvement of the ERK1/2/NF-κB signaling path-
ways in response to the exposure of human macrophages to 
the novel NP-siRNA liposomes.
As stated above, we have synthesized novel liposomal 
nanoparticles to encapsulate the three first-line anti-TB 
drugs, including INH, RIF, and PZA, and one second-line 
anti-TB drug, SM. These drugs are commonly used in 
clinical practice.5,81 SM was conjugated to PEG, and then 
encapsulated INH, RIF, and PZA and was formulated to be 
an orally administered complex. The N-terminal covalent 
bonding between SM and PEG facilitates the stabilization of 
the complex and has a substantial influence on the pharma-
cological activities of the complex. In comparison with the 
free drugs, the conjugated complex exhibits a low cytotoxic 
effect on human macrophages. Therefore, it will be clinically 
helpful to minimize the side effects. Furthermore, the newly 
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Table 3 The upregulated and downregulated proteins involved in TgF-β1-mediated signaling pathway in ThP-1-derived macrophages 
treated with the novel nP-sirna liposomes at 12.5 μg/ml for 24 hours
ID Gene in dataset Prediction (based on  
expression direction)
Fold changea Findingsb
P68104 EEF1A1 affected 1.676 regulated (1)
Q13509 TUBB3 activated 1.638 Upregulated (3)
B7Z6Z4 MYL6 activated 1.465 Upregulated (1)
Q01469 FABP5 activated 1.402 Upregulated (1)
P06753 TPM3 activated 1.392 Upregulated (9)
P28482 MAPK1 activated 1.310 Upregulated (4)
P00558 PGK1 inhibited 1.262 Downregulated (1)
P16070 CD44 inhibited 1.261 Downregulated (3)
e9PK25 CFL1 activated 1.155 Upregulated (1)
P06396-2 GSN inhibited 1.142 Downregulated (2)
Q01518 CAP1 activated 1.072 Upregulated (2)
P50552 VASP activated 1.031 Upregulated (2)
P26038 MSN activated 1.012 Upregulated (1)
P07900-2 HSP90AA1 activated 1.005 Upregulated (1)
Notes: aThe value indicates the ratio of heavy over light signal. bThe number in the brackets indicates the number of proteins involved.
Abbreviations: CAP1, CAP, adenylate cyclase-associated protein 1 (yeast); CD44, CD44 molecule (Indian blood group); CFL1, cofilin 1 (nonmuscle); EEF1A1, eukaryotic 
translation elongation factor 1 α1; FaBP5, fatty acid binding protein 5 (psoriasis-associated); gsn, gelsolin; hsP90aa1, heat shock protein 90 kDa α (cytosolic), class a 
member 1; MaPK1, mitogen-activated protein kinase 1; Msn, moesin; MYl6, myosin, light chain 6, alkali, smooth muscle and nonmuscle; PgK1, phosphoglycerate kinase 1; 
TPM3, tropomyosin 3; TUBB3, tubulin, β3 class iii; VasP, vasodilator-stimulated phosphoprotein.
synthesized liposomes can improve patient compliance and 
overcome the limitations of current anti-TB therapy.
Given the physicochemical properties of the novel NP-
siRNA liposomes, the results have demonstrated that the 
liposomes can be used to encapsulate the anti-TB drugs. 
The novel NP-siRNA liposomes are facile to be prepared, 
stabilized, and controlled in a reasonable size. These physi-
cochemical properties facilitate its internalization through 
the endocytosis by human macrophages. Moreover, the 
physicochemical properties determine the pharmacological 
and toxicological features of the novel NP-siRNA liposomes, 
such as absorption, distribution, metabolism, excretion, 
and toxicity. The favorable physicochemical properties of 
the newly synthesized NP-siRNA liposomes ensure their 
pharmacological effect in the treatment of TB. Indeed, this 
study showed that the novel NP-siRNA liposomes exhibit a 
slow drug release profile within the initial 12 hours compared 
with the free drugs. Notably, the novel NP-siRNA liposomes 
showed a sustained drug release profile between 12 and 
72 hours, which has great clinical importance in terms of 
enhancing the therapeutic effect and minimizing the side 
effects in the treatment of TB. Our biochemical assays dem-
onstrated that the novel NP-siRNA liposomes were safe and 
nontoxic to the host cells. The IC
50
 of the novel NP-siRNA 
liposomes was 269.5 μg/mL, which is lower than that of the 
combined four anti-TB drugs together. The novel NP-siRNA 
liposomes did not exert a significant impact on cell cycle dis-
tribution, apoptosis, and autophagy of human macrophages 
derived from THP-1 cells. There was an autophagy-inducing 
effect of NP-siRNA liposomes on human macrophages 
only at a high concentration of 62.5 μg/mL, but such high 
concentrations are not achieved in clinical practice. Col-
lectively, the novel NP-siRNA liposomes exhibit favorable 
physicochemical and biochemical properties that make it a 
promising therapy for TB treatment.
Combination chemotherapy is a basic principle to cure TB 
patients. Multiple drug chemotherapy is effective in curing 
TB, but with challenges and limitations. The major hurdles 
compromising the therapeutic outcome are poor compliance, 
drug resistance, and potential side effects. Current anti-TB 
drugs mainly interfere with the nucleotide metabolism and/
or the building of new bacterial walls; the treatment period 
of current anti-TB therapy is long (even the most potent 
medications have to be taken at least 6 months);82 and the 
anti-TB drugs development is slow. Therefore, increasing 
evidence shows that future studies need to focus on new 
therapeutic strategies to overcome the shortcomings of the 
current TB therapies, including polymeric drug delivery sys-
tems, vector construction, and genetic engineering methods. 
Anti-TB drugs formulated with nanoparticles are widely 
studied, such as polymer micelles, liposomes, nanospheres, 
nanotubes, nanobeads, etc, and there are some achievements 
in the treatment of TB in clinical settings.83 However, these 
nanomaterials combine only one or two kinds of commonly 
used anti-TB drugs, which limits their clinical application in 
the treatment of newly diagnosed TB and MDR-TB. In this 
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Figure 15 effect of the novel nP-sirna liposomes on the expression levels of p-erK, erK, nF-κB, and nrf2 in ThP-1-derived macrophages determined using Western 
blotting analysis.
Notes: (A) representative blots for p-erK, erK, nF-κB, and nrf2 in macrophages when treated with DMsO, nP, nP-sirna-control, and nP-sirna at 12.5 μg/ml for 
24 hours. (B) Bar graphs show the relative expression levels of the proteins in macrophages. (C) representative blot of nF-κB when macrophages were treated with the 
novel nP-sirna liposomes at 2.5, 12.5, and 62.5 μg/ml for 24 hours. (D) Bar graphs show the relative expression level of nF-κB in macrophages. The β-actin was used as the 
internal control. Data are the mean ± sD of three in dependent experiments. *P0.05; **P0.01; and ***P0.001 by one-way anOVa followed by Tukey’s post hoc test.
Abbreviations: anOVa, analysis of variance; DMsO, dimethyl sulfoxide; erK, extracellular signal-regulated kinase; nF-κB, nuclear factor-κB; nP, nanoparticle; nrf2, 
nuclear factor (erythroid-derived 2)-like 2; sD, standard deviation; sirna, small interfering rna.
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study, the data showed that the newly synthesized NP-siRNA 
liposomes encapsulated four anti-TB drugs and exhibited 
good physicochemical and biochemical properties toward 
human macrophages differentiated from THP-1 cells, which 
ensures its favorable pharmacological and toxicological 
profiles in the treatment of TB.
Although the ultrashort chemotherapy regimen to treat 
spinal TB has been applied in clinic,5,84 it has been noted 
that some patients experienced difficulty in adherence to 
the treatment in view of the long period involved. The poor 
patient compliance for anti-TB drugs often results in TB 
relapse, persisting disease, and the development of multi-
drug resistance. Therefore, novel drug delivery systems are 
incorporated to improve the existing therapy in terms of better 
efficacy, reduced drug toxicity, administration frequency, 
and shortened period of treatment.85 Encapsulating anti-TBs 
within nanoparticles can greatly enhance the bioavailability 
of the drugs, reduce the frequency of drug administration, and 
thereby achieve good compliance. As shown in this study, the 
novel NP-siRNA liposomes exert a sustainable drug release 
profile over 72 hours, indicating that the novel NP-siRNA 
liposomes may have great potential in reducing the frequency 
of drug administration and the drug treatment period.
While the therapeutic effect of anti-TB drugs can be 
improved with nanotechnology, it is important and indispens-
able to exploit host immune functions for the recognition of 
and protection against TB, especially in immunocompromised 
hosts and HIV-infected patients.82,86 In 10% of those infected 
patients, TB will erupt into full-blown disease in response to 
various stresses if the immune system is compromised.87 It has 
been well recognized that anti-TB progress happens mainly 
in macrophages that reflect the equilibrium between the host 
and pathogen. This leads to the attenuation of several cellular 
processes that include fusion of phagosomes with lysosomes, 
antigen presentation, apoptosis, and the bactericidal responses 
initiated by the macrophages. The process is mediated mainly 
by T-cells with the involvement of inflammatory responses, 
including inflammatory cytokines generation, such as 
TGF-β1; TNF-α; IFN-γ; and IL-1, 6, 8, and 10.56,58,59
After entry into the lungs, M. tuberculosis interacts 
with airway epithelial cells, alveolar Type II pneumocytes, 
alveolar macrophage, dendritic cells, and neutrophils.48,53,54,88 
Once in contact with M. tuberculosis, both alveolar Type 
II pneumocytes and airway epithelial cells may contribute 
to early host immune defense by generating various types 
of cytokines, chemokines, and other molecules includ-
ing TNF-α, IL-1α, IL-1β, IFN-γ, and chemoattractant 
molecules that may directly kill M. tuberculosis or enhance 
anti-TB activities of infected macrophages.53 In response to 
M. tuberculosis infection, chemokine (C-X-C motif) ligand 
8 (CXCL8) production by pulmonary epithelium and lung 
fibroblasts rapidly promotes the recruitment of neutrophils. 
In addition, infected dendritic cells migrating to local lymph 
nodes initiate an adaptive immune response, required for 
the arrest of growth of the bacterium and its entry into a 
latent phase. Other important players of the host response 
directed against M. tuberculosis infection are T lymphocytes 
and B cells.48,49,88 Notably, the primary pathologic feature of 
M. tuberculosis infection is the formation of granulomas.88 
The formation of an early granuloma is mainly regulated 
by TNF-α, and IFN-γ released from the infected cells to 
contain bacterial spread.54 At this early stage, the structure 
is composed of a central core of infected macrophages sur-
rounded by other macrophages differentiated in giant cells 
together with infected neutrophils.88 Accessory not-infected 
macrophages surround this structure powered by blood ves-
sels, which bring on the site of infection several cell types 
equipped to contain bacterial spread. At a later stage, the 
granuloma is composed primarily of CD4+ and CD8+ T-cells, 
but other T lymphocytes, including γδ T-cells, natural killers, 
and CD1-restricted αβ T-cells, are also present.49,53 TGF-β1 
plays a central role in the formation of TB granulomas, and 
TGF-β1 overexpression can cause tissue damage and fibro-
sis in TB patients.89,90 Excessive production of tuberculous 
granulomas compromises the therapeutic effect of anti-TB 
drugs. Consequently, M. tuberculosis can evade the host 
immune system and remain in the dormant stage for a long 
time, and TB can be reactivated to be a virulent form under 
the immunocompromised condition.91 Macrophage–pathogen 
interactions play a central role in TB pathogenesis. Owing to 
the key role of TGF-β1 in the pathogenesis of TB, it will be 
feasible to control TB infection by suppressing the expression 
of TGF-β1 with a combination of anti-TB drugs.
siRNA can efficiently and specifically silence the expres-
sion of homologous genes at the cellular level, promoting 
homologous mRNA degradation and inducing specific gene 
deletion phenotype.92,93 Cationic liposomes are the most stud-
ied nonviral delivery system used for nucleic acid delivery 
owing to the simplicity of the electrostatic interaction between 
cationic liposomes and negatively charged nucleic acids to 
form the vector complex. It has been used successfully for 
the intracellular delivery of siRNA. Therefore, siRNA with 
a negative charge is combined with positively charged lipo-
somes to form stable nanoparticles. The employment of the 
TGF-β1 siRNA-mediated gene silencing approach can reduce 
the expression of TGF-β1, thereby decreasing its translational 
products. The reduction of TGF-β1 leads to a decrease in the 
tuberculous granuloma formation.94 After M. tuberculosis 
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infection, proinflammatory cytokines, including TNF-α, IL-1, 
IL-6, and IL-18, and anti-inflammatory (IL-10) cytokines are 
secreted rapidly at high and sustained levels preferentially by 
M. tuberculosis-infected macrophages in the infected lung, 
while dendritic cells produce low or undetectable levels of 
these cytokines.53 Our data showed that the novel NP-siRNA 
liposomes were endocytosed by human macrophages and that 
the secretion of TGF-β1 was significantly reduced, whereas 
the ELISA results showed that the novel NP-siRNA lipo-
somes significantly increased the generation of IL-6, IL-8, 
TNF-α, and IFN-γ in THP-1-derived macrophages. More-
over, the gene expression level of TNF-α and IFN-γ  was 
increased, but there was no significant alteration in the 
gene expression level of IL-1, 6, and 8. Notably, it has been 
recently reported that IL-1 exerts a beneficial effect on the 
control of TB via the positive regulation of the eicosanoid 
network.59 In this study, the diverse regulatory effects of the 
novel NP-siRNA liposomes on the generation of cytokines 
may enhance the therapeutic effect in the treatment of TB. 
However, the carriers of the novel NP-siRNA complex may 
contribute to the increase in the expression of the proinflam-
matory cytokines, although the encapsulated anti-TB drugs 
may play a role. Thus, these regulatory effects of the novel 
NP-siRNA liposomes on the inflammatory response in human 
macrophages need to be further elucidated. Collectively, 
the novel NP-siRNA liposomes exhibit a potent modulating 
effect on the cytokine production, which may have substantial 
contributions to the treatment of TB in clinical practice.
Furthermore, we explored the molecular targets and 
the underlying mechanisms of the therapeutic effect of the 
novel NP-siRNA liposomes in human macrophages using the 
SILAC-based quantitative proteomic approach. The SILAC-
based quantitative proteomic approach can reveal a global 
and comprehensive molecular interactome including the 
therapeutic and toxicological targets, and discriminate the dif-
ferential responses to drug exposure.69,70,95,96 In this study, the 
proteomic results showed that inflammatory response associ-
ated signaling pathways were profoundly regulated by the 
novel NP-siRNA liposome treatment in human macrophages. 
In particular, ERK1/2 and NF-κB were closely orchestrated in 
response to the exposure of human macrophages to the novel 
NP-siRNA liposomes. Subsequently, our initial validation 
results demonstrated that the novel NP-siRNA enhanced the 
phosphorylation of ERK1/2 while suppressing the expression 
of NF-κB in THP-1-differentiated macrophages, indicating 
that the newly synthesized NP-siRNA liposomes regulated 
ERK1/2 and NF-κB signaling pathways, contributing to the 
diverse regulatory effects on the expression of TNF-α, IFN-γ, 
IL-1, 6, and 8. Indeed, extensive studies show that ERK1/2/
NF-κB play a critical role in a variety of cellular processes, 
such as cytokine generation,77 and that aberrations in ERK1/2/
NF-κB signals have been implicated in many pathologies, 
including infectious diseases.78 Thus, the regulatory effects of 
the novel NP-siRNA liposomes on ERK1/2/NF-κB signaling 
pathways make a substantial contribution to the cytokines 
production in macrophages with the dependence of TGF-β1. 
However, these effects need to be further examined. Taken 
together, given the critical role of TGF-β1 in the formation of 
tuberculous granuloma, combining TGF-β1 siRNA is more 
conducive to the enhancement of the therapeutic effect of 
anti-TB drugs in macrophages by targeting ERK1/2/NF-κB 
signaling pathways.
In summary, a facile approach has been developed to fabri-
cate a liposomal nanoparticle with favorable physicochemical 
properties for the codelivery of multiple anti-TB drugs as well 
as the anti-TGF-β1 siRNA simultaneously. The TEM mea-
surements monitoring the drug uptake process at both 37°C 
and 4°C reveal that the liposomal nanoparticles are engulfed 
through endocytosis by THP-1-derived macrophages. The 
liposomal nanoparticles possess a sustained drug release pro-
file over 72 hours, which may help to improve compliance in 
conventional anti-TB therapy. Notably, the biochemical assays 
and SILAC-based quantitative proteomics show that the NP-
siRNA liposomes display minimal cytotoxicity and exhibit 
maximum transfection efficiency against the target gene in 
human macrophages. Furthermore, the novel NP-siRNA 
liposomes exhibit diverse modulating effects on cytokine gen-
eration with the involvement of ERK1/2 and NF-κB signaling 
pathways in human macrophages. Collectively, the novel 
synthetic targeting liposomes represent a promising delivery 
system for anti-TB drugs that may improve the therapeutic 
effect and reduce the side effects in clinical practice.
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